Pfizer emergency Supreme Court request
Executive Summary
Pfizer asks the Supreme Court May 29 to vacate the Federal Circuit U.S. Court of Appeals' ruling that its Norvasc patent is invalid until the court takes action on its concurrently filed petition for certiorari. The Federal Circuit denied Pfizer's request for an en banc review of its decision (1"The Pink Sheet" May 28, 2007, p. 23). Pfizer argues that the Federal Circuit "used a flawed analytical framework" in applying the Supreme Court's recent ruling in KSR v. Teleflex as to what constitutes an obvious patent...You may also be interested in...
Federal Circuit Denies En Banc Review of Norvasc Decision
The pharmaceutical and biotech industries were dealt a blow when the Federal Circuit U.S. Court of Appeals decided not to reconsider its ruling that Pfizer's Norvasc (amlodipine besylate) patent is obvious
Health And Wellness Trademark Review 14 January, 2020
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention
Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: